glp 1 and heart GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, Emerging Therapies Heart transplantation in the GLP-1

2.2 Rat studies Studies with laboratory rats were conducted in accordance with the standards of the Federal Republic of Germany (similar to AAALAC equivalents) under license numbers SYN01/16, SYN07/20, and SYN01/22, provided by the Regierungsprsidium Tbingen ethics committee

The honest answer is yes

Saxenda is approved for: Adults Adults with obesity (BMI of 30 kg/m or greater) Adults who are overweight (BMI of 27 kg/m or greater) and have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol Children aged 12 and older Adolescents with obesity who weigh more than 60 kg (132 pounds) Limitations of use Saxenda should not be used together with other medicines that contain liraglutide, such as Victoza, or with any other GLP-1 receptor agonist, such as Ozempic, Wegovy, or Trulicity The safety and effectiveness of Saxenda in children aged 12 to 17 years who have type 2 diabetes have not been established

This threshold may vary for different ethnic groups due to varying obesity classifications

NAR Cancer